Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP, Pedersen-Bjergaard J, Ellegaard J, Brincker H, Boesen AM, Christensen BE, Drivsholm A, Hippe E, Jans H, Jensen KB, et al. Hansen OP, et al. Among authors: boesen am. Leukemia. 1991 Jun;5(6):510-6. Leukemia. 1991. PMID: 2056774 Clinical Trial.
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AML.
de Nully Brown P, Hoffmann T, Hansen OP, Boesen AM, Grønbaek K, Hippe E, Jensen MK, Thorling K, Storm HH, Pedersen-Bjergaard J. de Nully Brown P, et al. Among authors: boesen am. Leukemia. 1997 Jan;11(1):37-41. doi: 10.1038/sj.leu.2400514. Leukemia. 1997. PMID: 9001416 Clinical Trial.
Clinicopathological features, survival and prognostic factors of primary central nervous system lymphomas: trends in incidence of primary central nervous system lymphomas and primary malignant brain tumors in a well-defined geographical area. Population-based data from the Danish Lymphoma Registry, LYFO, and the Danish Cancer Registry.
Krogh-Jensen M, D'Amore F, Jensen MK, Christensen BE, Thorling K, Pedersen M, Johansen P, Boesen AM, Andersen E. Krogh-Jensen M, et al. Among authors: boesen am. Leuk Lymphoma. 1995 Oct;19(3-4):223-33. doi: 10.3109/10428199509107892. Leuk Lymphoma. 1995. PMID: 8535213
Incidence, clinicopathological features and outcome of primary central nervous system lymphomas. Population-based data from a Danish lymphoma registry. Danish Lymphoma Study Group, LYFO.
Krogh-Jensen M, d'Amore F, Jensen MK, Christensen BE, Thorling K, Pedersen M, Johansen P, Boesen AM, Andersen E. Krogh-Jensen M, et al. Among authors: boesen am. Ann Oncol. 1994 Apr;5(4):349-54. doi: 10.1093/oxfordjournals.annonc.a058839. Ann Oncol. 1994. PMID: 8075032 Free article.
Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous stem cell support.
Johnsen HE, Björkstrand B, Carlson K, Gruber A, Blystad A, Fast A, Boesen AM, Björkholm M, Sallerfors B, Ruutu T, Carneskog J, Malm A, Geisler C, Lehtinen M, Schrøder H, Brinch L, Remes K, Tidefelt U, Heilmann C, Hörnsten P, Thorling K, Daugaard G. Johnsen HE, et al. Among authors: boesen am. Leuk Lymphoma. 1996 Dec;24(1-2):81-91. doi: 10.3109/10428199609045716. Leuk Lymphoma. 1996. PMID: 9049964
40 results